title: Preoperative concurrent chemoradiotherapy for stage IIIA non-small cell lung cancer.
abstract: Thirty-one patients with stage IIIA non-small cell lung cancer (NSCLC) were treated with preoperative concurrent chemoradiotherapy (CCRT) followed by surgery. The treatment protocol could not be completed in eight patients. The acute hematologic toxicities of grade III or IV occurred in 48.4%, (15/31) after the first chemotherapy cycle, and in 39.1% (9/23) after the second cycle. The most common non-hematologic toxicity was radiation esophagitis. Surgery was attempted in 23 patients and successful in 22 patients (resection rate = 71.0%. Pathologic complete response and down-staging were achieved in 13.6% (3/22) and 68.2% (15/22). The median survival period, 2-year overall survival, local control and disease-free survival rates of all 31 patients and of 22 patients who underwent surgery were 19 months, 37.2%, 49.1%, 35.5%, and 19 months, 43.2%, 51.8%, 25.6%, respectively. On the basis of our observations, preoperative CCRT followed by surgery for stage IIIA NSCLC has resulted in outcomes comparable with those in previous reports.
authors.affiliation: Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. ycahn@smc.samsung.co.kr
authors.forename: Y C
authors.initials: YC
authors.lastname: Ahn
authors.forename: K
authors.initials: K
authors.lastname: Park
authors.forename: D Y
authors.initials: DY
authors.lastname: Kim
authors.forename: K M
authors.initials: KM
authors.lastname: Kim
authors.forename: J
authors.initials: J
authors.lastname: Kim
authors.forename: Y M
authors.initials: YM
authors.lastname: Shim
authors.forename: K S
authors.initials: KS
authors.lastname: Lee
authors.forename: J
authors.initials: J
authors.lastname: Han
authors.forename: H J
authors.initials: HJ
authors.lastname: Kim
authors.forename: J
authors.initials: J
authors.lastname: Kwon
authors.forename: D H
authors.initials: DH
authors.lastname: Lim
authors.forename: Y J
authors.initials: YJ
authors.lastname: Noh
authors.forename: J E
authors.initials: JE
authors.lastname: Lee
authors.forename: S J
authors.initials: SJ
authors.lastname: Huh
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D004941:Esophagitis / Q000209:etiology; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006402:Hematologic Diseases / Q000209:etiology; D006801:Humans; D015993:Life Tables; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011013:Pneumonectomy; D011300:Preoperative Care; D011446:Prospective Studies; D011832:Radiation Injuries / Q000209:etiology; D011867:Radioisotope Teletherapy / Q000009:adverse effects; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D005047:Etoposide; D002945:Cisplatin